WEBSITE BSE:544643 NSE: PRODOCS Inc. Year: 2019 Industry: BPO/ITeS My Bucket: Add Stock
Last updated: 11:21
No Notes Added Yet
Prodocs Solutions Ltd. is a niche technology solutions provider focused on regulatory, quality, and compliance management for the global life sciences industry. The company offers software platforms and specialized services that support pharmaceutical, biotechnology, and medical device companies in managing complex regulatory submissions, product registrations, clinical documentation, and quality management systems across multiple geographies. Its solutions are designed to align with stringent international regulatory frameworks such as USFDA, ...Read More
Prodocs Solutions Ltd. is a niche technology solutions provider focused on regulatory, quality, and compliance management for the global life sciences industry. The company offers software platforms and specialized services that support pharmaceutical, biotechnology, and medical device companies in managing complex regulatory submissions, product registrations, clinical documentation, and quality management systems across multiple geographies. Its solutions are designed to align with stringent international regulatory frameworks such as USFDA, EMA, MHRA, and other global health authorities, helping clients reduce compliance risk and improve operational efficiency. The company’s business model combines domain-driven consulting with technology-led platforms, enabling long-term client relationships and recurring revenue through ongoing regulatory support and system maintenance. Prodocs Solutions benefits from deep industry expertise, a skilled regulatory workforce, and increasing demand for digital transformation in regulatory affairs as life sciences companies expand into new markets and face rising compliance scrutiny. With regulatory complexity and global drug approvals continuing to increase, Prodocs is positioned to benefit from sustained demand for specialized compliance and documentation solutions. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹133 Cr.
Stock P/E 26
P/B 3.2
Current Price ₹188.8
Book Value ₹ 58.5
Face Value 10
52W High ₹254.3
Dividend Yield 0%
52W Low ₹ 141
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|
| Net Sales | 10 | 37 | 45 | 42 | |
| Other Income | 0 | 0 | 0 | 1 | |
| Total Income | 10 | 37 | 46 | 43 | |
| Total Expenditure | 10 | 35 | 41 | 35 | |
| Operating Profit | 0 | 2 | 5 | 8 | |
| Interest | 0 | 0 | 0 | 1 | |
| Depreciation | 0 | 0 | 0 | 1 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | |
| Profit Before Tax | 0 | 2 | 4 | 6 | |
| Provision for Tax | 0 | 0 | 1 | 1 | |
| Profit After Tax | 0 | 2 | 3 | 5 | |
| Adjustments | 0 | 0 | 0 | 0 | |
| Profit After Adjustments | 0 | 2 | 3 | 5 | |
| Adjusted Earnings Per Share | 0.4 | 3.8 | 7.8 | 9.4 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -7% | 61% | 0% | 0% |
| Operating Profit CAGR | 60% | 0% | 0% | 0% |
| PAT CAGR | 67% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 41% | 63% | 51% | 51% |
| ROCE Average | 42% | 57% | 44% | 44% |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Shareholder's Funds | 1 | 3 | 6 | 19 |
| Minority's Interest | 0 | 0 | 0 | 0 |
| Borrowings | 1 | 0 | 2 | 4 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 1 |
| Total Current Liabilities | 3 | 4 | 5 | 11 |
| Total Liabilities | 5 | 8 | 13 | 35 |
| Fixed Assets | 0 | 1 | 1 | 3 |
| Other Non-Current Assets | 1 | 1 | 1 | 2 |
| Total Current Assets | 4 | 5 | 11 | 30 |
| Total Assets | 5 | 8 | 13 | 35 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 0 |
| Cash Flow from Operating Activities | -1 | 3 | 3 | 3 |
| Cash Flow from Investing Activities | -1 | -2 | -3 | -16 |
| Cash Flow from Financing Activities | 2 | -1 | 1 | 13 |
| Net Cash Inflow / Outflow | 0 | -0 | -0 | 0 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 0 |
| # | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.44 | 3.8 | 7.81 | 9.37 |
| CEPS(Rs) | 0.49 | 4.32 | 9 | 10.86 |
| DPS(Rs) | 0 | 0.03 | 0.2 | 0 |
| Book NAV/Share(Rs) | 3.1 | 6.9 | 14.48 | 35.21 |
| Core EBITDA Margin(%) | 2.45 | 5.45 | 9.67 | 17.21 |
| EBIT Margin(%) | 2.61 | 5.41 | 9.11 | 17.64 |
| Pre Tax Margin(%) | 2.58 | 4.64 | 8.23 | 15.37 |
| PAT Margin (%) | 1.8 | 4.21 | 6.96 | 12.22 |
| Cash Profit Margin (%) | 2.02 | 4.77 | 8.03 | 14.16 |
| ROA(%) | 3.44 | 23.99 | 30.68 | 21.26 |
| ROE(%) | 14.19 | 76.01 | 73.06 | 40.78 |
| ROCE(%) | 7.88 | 57.11 | 71.03 | 41.9 |
| Receivable days | 89.77 | 22.54 | 26.06 | 60.2 |
| Inventory Days | 0 | 0 | 0 | 0 |
| Payable days | 0 | 0 | 0 | 0 |
| PER(x) | 0 | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.2 | 0.02 | 0.06 | 0.32 |
| EV/Core EBITDA(x) | 6.96 | 0.38 | 0.63 | 1.61 |
| Net Sales Growth(%) | 0 | 269.07 | 24.08 | -8.01 |
| EBIT Growth(%) | 0 | 663.38 | 109.03 | 78.07 |
| PAT Growth(%) | 0 | 764.14 | 105.46 | 61.46 |
| EPS Growth(%) | 0 | 764.14 | 105.46 | 19.99 |
| Debt/Equity(x) | 1.62 | 0.3 | 0.37 | 0.42 |
| Current Ratio(x) | 1.36 | 1.26 | 2.09 | 2.68 |
| Quick Ratio(x) | 1.36 | 1.26 | 2.09 | 2.68 |
| Interest Cover(x) | 66.51 | 7.01 | 10.32 | 7.79 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 |
| # | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|
| Promoter | 0 | 51.77 | 51.99 |
| FII | 0 | 6.77 | 3.7 |
| DII | 0 | 6.43 | 1.08 |
| Public | 0 | 35.04 | 43.23 |
| Others | 0 | 0 | 0 |
| Total | 0 | 100 | 100 |
| # | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|
| Promoter | 0 | 0.37 | 0.37 |
| FII | 0 | 0.05 | 0.03 |
| DII | 0 | 0.05 | 0.01 |
| Public | 0 | 0.25 | 0.3 |
| Others | 0 | 0 | 0 |
| Total | 0 | 0.71 | 0.71 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
